• Home
  • PR

PR

News

게시물 상세
OliX Pharmaceuticals Announces Expansion of Collaboration with Laboratoires Théa
Date : 2020-10-21     View : 627

OliX Pharmaceuticals Announces Expansion of Collaboration with Laboratoires Théa to Develop siRNA Therapeutics for Ophthalmic Diseases

 

- Companies to broaden their existing partnership on Age-related Macular Degeneration (AMD) treatments

- OliX grants Théa worldwide rights excluding Asia-Pacific on OLX301A and OLX301D, targeting dry/wet AMD and wet AMD/subretinal fibrosis, respectively

- OliX further grants Théa option to nominate two additional ophthalmic programs

- Théa to invest €8.8 million through upfront payment for two AMD programs and an option fee for two additional ophthalmic programs

 

Learn more: https://finance.yahoo.com/news/olix-pharmaceuticals-announces-expansion-collaboration-130000090.html 

 

Source _ OliX Pharmaceuticals

 

Prev OliX Announces FDA Clearance of the Phase 2a Clinical Trial IND for Hypertrophic Scars
Next OliX Moves Into Spotlight Amid Strong RNAi Interest, New Platform